Galapagos Announces Major Restructuring with Split into Two Publicly Traded Companies

Galapagos Announces Major Restructuring with Split into Two Publicly Traded Companies
5 months ago

In a significant strategic move, the biotechnology firm Galapagos has revealed its decision to split into two distinct publicly traded entities. This restructuring initiative aims to streamline operations and enhance focus on its core business areas. This news marks a pivotal moment for the company, which has sought to navigate challenges in the competitive biotech landscape.

Continue reading
Merck Expands Cancer Drug Portfolio with $3.3 Billion Agreement in China

Merck Expands Cancer Drug Portfolio with $3.3 Billion Agreement in China
7 months ago

In a significant move to bolster its cancer treatment offerings, Merck & Co. has secured a lucrative agreement with a Chinese biotech company, attaching itself to a compelling late-stage cancer therapy. The deal, which could reach a staggering $3.3 billion, is centered around the promising drug known as sugemalimab, known for its potential effectiveness against various tumors.

Continue reading